Healx raises €42.3M Series C round
1 August 2024· Cambridge, United Kingdom· health, biotech, ai, drug_discovery, pure_software, b2b
Proceeds of the financing will be used to advance the company's pipeline of medicines in rare oncology, renal and neurodevelopmental disorders, including advancing its lead program HLX-1502 through a Phase 2 clinical trial for the treatment of neurofibromatosis Type 1 (NF1). The company also plans to expand its presence in the U.S. for upcoming clinical trials.
Investors
LeadAtomico
Also participating
Baldertonbtov PartnersGlobal BrainR42 GroupAyana CapitalJonathan MilnerO2hVU Venture Partners
About Healx
Stage
Series C
Headquarters
Cambridge, United Kingdom
Founded
2014
Team Size
51–200
Sectors
healthbiotechaidrug_discoverypure_softwareb2b